Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Eugia Steriles receives EIR from USFDA for new injectable facility
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Subscribe To Our Newsletter & Stay Updated
